A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

NCT ID: NCT01007630

Last Updated: 2013-12-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2014-01-31

Brief Summary

A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease.

Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.

Detailed Description

This study will last approximately 10 weeks.

• 2 visits to The Parkinson's Institute in Sunnyvale, California
• 1 phone call between visits

You will be asked to take either Rasagiline (Azilect) or placebo (an identical pill without active ingredients)

• 5 in 6 chance of receiving Rasagiline (Azilect)
• 1 in 6 chance of receiving placebo
• Neither you nor the study team will know which you are assigned
• This information will be available in case of emergency

To be eligible for this study, you must:

• be 90 years old or younger
• have a decreased loss of smell or complete loss of smell
• have not taken Selegiline or Rasagiline within the past 12 months
• have not smoked within the last year
• be on a stable dose of Parkinson's medication (or not on any PD medicines)
• have no history of head trauma, nasal surgery, nasal inflammation causing congestion or polyps, nasal/sinus infection, or prior Zicam use
• have not used decongestants, antihistamine or inhaled steroids within 2 weeks of the study and be willing to avoid such treatments during the study

Conditions

Parkinson's Disease

Keywords

Parkinson's; Parkinsons; Parkinson; Parkinson's Disease; PD; Rasagiline; Azilect; Olfactory; Sense of Smell; UPSIT

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Rasagiline

0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).

Group Type: ACTIVE_COMPARATOR

Rasagiline

Intervention Type: DRUG

0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)

Placebo

0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)

Interventions

Rasagiline

0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)

Intervention Type: DRUG

Placebo

0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)

Intervention Type: DRUG

Other Intervention Names

Brand Name: Azilect

Eligibility Criteria

Inclusion Criteria

• Men and women with Parkinson's Disease (PD), defined as the presence of at least two of the cardinal signs of PD (bradykinesia, resting tremor, rigidity) without other identifiable cause of parkinsonism or signs of atypical parkinsonism
• Functional hyposmia or anosmia, as defined by UPSIT scores less than the 25th percentile for age- and gender-matched norms
• Have been on stable dose of PD medications for at least 30 days
• Age < or = 90 years
• Willing and able to give informed consent
• Women of child-bearing potential may participate provided they are willing to use adequate contraceptive methods during the duration of the study. Women of childbearing potential must have a negative pregnancy test at the screening visit and be non-lactating.

Exclusion Criteria

• Prior use of an MAO inhibitor, including selegiline or rasagiline within the last 12 months
• Presence of other conditions that in the investigator's opinion may significantly cause olfactory impairment, including prior head trauma, nasal surgery, nasal inflammation causing concurrent congestion or polyps, nasal or sinus infection, prior intranasal zinc salt (Zicam) use, history of smoking within the past year
• Presence of dementia or significant cognitive impairment with Mini-Mental State Examination (MMSE) < 24
• Present of a medical or surgical condition which in the opinion of the investigator would preclude participation in and completion of study procedures
• Use of any experimental medication within 60 days of baseline
• Use of decongestants, antihistamines, inhaled steroids within 2 weeks of baseline
• Use of any medication contraindicated with use of rasagiline (Investigator will take into consideration concomitant antidepressant use as per prescribing information guidelines for rasagiline)

• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Teva Neuroscience, Inc.

INDUSTRY

Sponsor Role: collaborator

The Parkinson's Institute

OTHER

Sponsor Role: lead

Responsible Party

Grace Liang

Principal Investigator, Director of Clinical Trials

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Grace S Liang, MD

Role: PRINCIPAL_INVESTIGATOR

The Parkinson's Institute

Locations

The Parkinson's Institute

Sunnyvale, California, United States

Countries

United States

Related Links

http://thepi.org/index.php?submenu=clinical_trials&src=gendocs&ref=ClinicalTrialsMain&category=clinical_trials

The Parkinson's Institute Clinical Trials Website

Other Identifiers

PD-SOAR

Identifier Type: -

Identifier Source: org_study_id